A pharmacist whose application for licensure has been denied or revoked or suspended for unprofessional conduct shall be eligible to be registered as a pharmacy technician.
A pharmacist whose application for licensure has been denied or revoked or suspended for unprofessional conduct shall be eligible to be registered as a pharmacy technician.
Answer: False, [Administrative Rules Vermont Board of Pharmacy Part 5 Section 5.2(b)].
No person who has:
(1). held a pharmacist license, or
(2). whose application for licensure has been denied or revoked or suspended for unprofessional conduct shall be eligible to be registered as a pharmacy technician unless the Board, in its sole discretion, determines that good cause exists to register the individual.
Which of the following statement(s) is/are TRUE under the Vermont State Pharmacy Law?
I. All drug outlets shall biennially register with the board of pharmacy.
II. Any nonpublic corporation owning a retail or institutional drug outlet, upon application, shall declare all owners of five percent or more of the stock of the corporation.
III. Retail and institutional drug outlets shall be managed by licensed pharmacists who have held an unrestricted license in this or another state for at least 3 years.
a. I only b. I and II only c. All d. None of the above
Which of the following statement(s) is/are TRUE under the Vermont State Pharmacy Law?
I. All drug outlets shall biennially register with the board of pharmacy.
II. Any nonpublic corporation owning a retail or institutional drug outlet, upon application, shall declare all owners of five percent or more of the stock of the corporation.
III. Retail and institutional drug outlets shall be managed by licensed pharmacists who have held an unrestricted license in this or another state for at least 3 years.
a. I only b. I and II only c. All d. None of the above
Answer: I and II only, [Vermont Statues Title 26 Chapter 36 Section 2061].
(a). All drug outlets shall biennially register with the board of pharmacy.
(b). Each drug outlet shall apply for a license in one of the following classifications:
(1). Retail drug outlet;
(2). Institutional drug outlet;
(3). Manufacturing drug outlet;
(4). Wholesale drug outlet or wholesale drug distributor;
(5). Investigative and research projects.
(c). No individual who is employed by a corporation which is licensed under any classification listed in subsection (b) of this section need obtain a license under the provisions of this subchapter.
(d). The board shall establish by rule under the powers granted to it under section 2032 of this title and 3 V.S.A. chapter 25, the criteria which each drug outlet, that has employees or personnel engaged in the practice of pharmacy, must meet to qualify for licensure in each classification designated in subsection (b) of this section.
The board may issue various types of licenses with varying restrictions to such outlets referred to in this subsection where the board deems it necessary by reason of the type drug outlet requesting a license.
(e). Retail and institutional drug outlets shall be managed by licensed pharmacists who have held an unrestricted license in this or another state for at least one year (Not 3 years). A pharmacist who holds a restricted license may petition the board for permission to be a pharmacist manager, which may be granted by the board for good cause shown.
(f). Any nonpublic corporation owning a retail or institutional drug outlet, upon application, shall declare all owners of five percent or more of the stock of the corporation.
If a pharmacist selects a pharmaceutically equivalent drug product for a prescribed product, the selected pharmaceutically equivalent drug product may not be rated less than ___________ as documented in Approved Drug Products with Therapeutic Equivalence Evaluations.
a. AB b. BD c. BS d. EE
If a pharmacist selects a pharmaceutically equivalent drug product for a prescribed product, the selected pharmaceutically equivalent drug product may not be rated less than ___________ as documented in Approved Drug Products with Therapeutic Equivalence Evaluations.
An equivalent drug product is a drug product that is considered to be pharmaceutically equivalent to a drug product that contains the same active ingredient(s) as determined by the Food and Drug Administration in Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition, 1999 (orange book).
If a pharmacist selects a pharmaceutically equivalent drug product for a prescribed product, the selected pharmaceutically equivalent drug product may not be rated less than AB as documented in Approved Drug Products with Therapeutic Equivalence Evaluations (orange book).
I. Perform drug administration pursuant to a prescription drug order.
II. Perform or participate in scientific or clinical drug or drug-related research as an investigator or in collaboration with other investigators.
III. Interpret and apply pharmacokinetic data and other pertinent laboratory data to design safe and effective drug dosage regimens.
a. I only b. I and II only c. All d. None of the above
Registered pharmacists in South Dakota may:
I. Perform drug administration pursuant to a prescription drug order.
II. Perform or participate in scientific or clinical drug or drug-related research as an investigator or in collaboration with other investigators.
III. Interpret and apply pharmacokinetic data and other pertinent laboratory data to design safe and effective drug dosage regimens.
a. I only b. I and II only c. All d. None of the above
Answer: All, [South Dakota Statue 36-11-19.1].
Registered pharmacists may:
(1). Perform drug administration pursuant to a prescription drug order. The Board of Pharmacy shall establish standards for drug administration pursuant to chapter 1-26 with the approval of a committee composed of two persons appointed by the Board of Pharmacy, two persons appointed by the Board of Nursing and two persons appointed by the Board of Medical and Osteopathic Examiners;
(2). Perform drug reviews;
(3). Perform or participate in scientific or clinical drug or drug-related research as an investigator or in collaboration with other investigators;
(4). Interpret and apply pharmacokinetic data and other pertinent laboratory data to design safe and effective drug dosage regimens;
(5). Participate in drug and drug device selection pursuant to a prescription drug order;
(6). Initiate or modify drug therapy by protocol or other legal authority established and approved within a licensed health care facility or by a practitioner authorized to prescribe drugs; and
(7). Provide information on prescription drugs, which may include advising, consulting, and educating, as necessary or as required, patients, the public, and other health care providers on the rational, safe and cost-effective use of drugs, including therapeutic values, content, hazards and appropriate use.
When the pharmacy is remodeling within existing permitted space or when a pharmacy is attempting to improve toward the standards mentioned in North Dakota Administrative Code, the board may grant approval to move toward the standards EVEN THOUGH the amount of space available DOES NOT allow complete compliance with the standards.
True or False
When the pharmacy is remodeling within existing permitted space or when a pharmacy is attempting to improve toward the standards mentioned in North Dakota Administrative Code, the board may grant approval to move toward the standards EVEN THOUGH the amount of space available DOES NOT allow complete compliance with the standards.
When the pharmacy is remodeling within existing permitted space or when a pharmacy is attempting to improve toward the standards in section 61-02-02-01 or chapters 61-02-03 or 61-02-04, the board may grant approval to move toward the standards even though the amount of space available does not allow complete compliance with the standards.
Each pharmacy shall notify the board of pharmacy immediately upon knowledge of the termination of the services of the pharmacist-in-charge and further, shall immediately designate a successor pharmacist-in-charge and notify the board of pharmacy of such designation.
The board of pharmacy upon receiving such notice shall furnish the successor pharmacist-in-charge with all necessary forms required to be completed by the successor pharmacist-in-charge. Such forms shall be completed and filed with the board within ten days after receipt.
Which of the statement(s) is/are NOT TRUE under the Rhode Island State Pharmacy Law?
I. When a change of ownership of services is contemplated, the owner shall notify the Department in writing at least 14 days prior to the proposed action.
II. When discontinuation of services is contemplated, the owner shall notify the Department in writing at least 30 days prior to the proposed action.
III. When a pharmacist-in-charge of a pharmacy services is terminated, the owner shall notify the Department in writing at least 72-hour prior to the proposed action.
a. I only b. I and II only c. II and III only d. All
Which of the statement(s) is/are NOT TRUE under the Rhode Island State Pharmacy Law?
I. When a change of ownership of services is contemplated, the owner shall notify the Department in writing at least 14 days prior to the proposed action.
II. When discontinuation of services is contemplated, the owner shall notify the Department in writing at least 30 days prior to the proposed action.
III. When a pharmacist-in-charge of a pharmacy services is terminated, the owner shall notify the Department in writing at least 72-hour prior to the proposed action.
a. I only b. I and II only c. II and III only d. All
Answer: II and III are NOT TRUE, [Rules and Regulations Pertaining to Pharmacists, Pharmacies and Manufacturers, Wholesalers and Distributors - Part II Section 12].
12.1 When a change of ownership or location or when discontinuation of services is contemplated, the owner shall notify the Department in writing at least fourteen (14) days prior to the proposed action.
12.2 The pharmacy owner shall give the Department fourteen (14) days' notice in writing prior to terminating services of a pharmacist-in-charge of a pharmacy, unless the pharmacist-incharge vacates the position without notice. In this instance, the Department shall be notified in writing immediately of the change in pharmacist-in-charge.
12.3 When there is a change in ownership and/or location, the license shall immediately become void and shall be delivered to the Department.
12.3.1 The Board, or its designee, reserves the right to extend the expiration date of such license, allowing the pharmacy to operate, but under conditions stipulated by the Board for such time as shall be required for the processing of a new application.
12.3.2 The new applications must be filed accompanied by the initial licensure fee.
12.4 Any renovations or remodeling of an existing pharmacy shall not be considered a change of location.
12.5 Patient records shall be retained and shall be capable of being retrieved for no less than two (2) years after a change of ownership is completed.
Which of the following shall be placed on the label of multi-drug single-dosing container?
I. The name of the prescribing practitioner of each drug.
II. The name, strength, exact physical description, and total quantity of each drug contained therein.
III. The identifying serial number assigned to the prescription drug order for each drug contained therein.
a. I only b. I and II only c. II and III only d. All
Which of the following shall be placed on the label of multi-drug single-dosing container?
I. The name of the prescribing practitioner of each drug.
II. The name, strength, exact physical description, and total quantity of each drug contained therein.
III. The identifying serial number assigned to the prescription drug order for each drug contained therein.
a. I only b. I and II only c. II and III only d. All
Answer: All, [Rules and Regulations Pertaining to Pharmacists, Pharmacies and Manufacturers, Wholesalers and Distributors - Part II Section 8.3.6].
8.3.6 Each individual, customized, multi-drug single-dosing container shall bear a label, which, at a minimum, contains the following:
(a). The name of the patient;
(b). The name of the prescribing practitioner of each drug;
(c). The identifying serial number assigned to the prescription drug order for each drug contained therein;
(d). The name, strength, exact physical description, and total quantity of each drug contained therein;
(e). The directions for use, and/or time of administration or time to be taken for each individual multi-drug single-dosing container;
(f). Either the dispensing or preparation date, as well as a beyond-use (expiration) date for each drug contained in the multi-drug single-dosing container. The expiration date of each drug included therein shall not be longer than one (1) year from the date of preparation of the multi-drug single-dosing container. All drugs shall be packaged in accordance with USP standards.
8.3.7 The name, address, and telephone number of the pharmacy issuing the multi-drug single dosing container and any cautionary statements necessary for the proper administration or storage of the medication shall appear on the individualized patient container.
The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:
a. "Start Talking!" b. "Minor Opioid" c. "Opioid Consequences" d. “Minor Consent”
The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:
a. "Start Talking!" b. "Minor Opioid" c. "Opioid Consequences" d. “Minor Consent”
(1). As part of the prescriber's examination of the minor, assess whether the minor has ever suffered, or is currently suffering, from mental health or substance abuse disorders and whether the minor has taken or is currently taking prescription drugs for treatment of those disorders;
(2). Discuss with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment all of the following:
(a). The risks of addiction and overdose associated with the compound;
(b). The increased risk of addiction to controlled substances of individuals suffering from both mental and substance abuse disorders;
(c). The dangers of taking controlled substances containing opioids with benzodiazepines, alcohol, or other central nervous system depressants;
(d). Any other information in the patient counseling information section of the labeling for the compound required under 21 C.F.R. 201.57(c)(18).
(3). Obtain written consent for the prescription from the minor's parent, guardian, or, subject to division (E) of this section, another adult authorized to consent to the minor's medical treatment.
The prescriber shall record the consent on a form, which shall be known as the "Start Talking!" consent form. The form shall be separate from any other document the prescriber uses to obtain informed consent for other treatment provided to the minor. The form shall contain all of the following:
(a). The name and quantity of the compound being prescribed and the amount of the initial dose;
(b). A statement indicating that a controlled substance is a drug or other substance that the United States drug enforcement administration has identified as having a potential for abuse;
(c). A statement certifying that the prescriber discussed with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment the matters described in division (B)(2) of this section;
(d). The number of refills, if any, authorized by the prescription;
(e). The signature of the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment and the date of signing.
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
III. The name, address, and telephone number of the dispenser.
a. I only b. I and II only c. II and III only d. All
The patient med pak shall bear a label stating:
I. A serial number for the patient med pak.
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
III. The name, address, and telephone number of the dispenser.
a. I only b. I and II only c. II and III only d. All
Answer: All, [Title 20 Code of State Regulations (CSR) 2220-2.145(2)(A)].
(A). The patient med pak shall bear a label stating—
1. The name of the patient;
2. A serial number for the patient med pak itself and a separate identifying serial number for each of the prescription orders for each of the drug products contained therein;
3. The name, strength, physical description or identification and total quantity of each drug product contained therein;
4. The directions for use and cautionary statements if any, contained in the prescription order for each drug product therein;
5. Any storage instructions or cautionary statements required by the official compendia;
6. The name of the prescriber of each drug product;
7. The date of preparation of the patient med pak and the beyond-use date assigned to the patient med pak (such beyond-use date shall be not later than sixty (60) days from the date of preparation);
8. The name, address, and telephone number of the dispenser; and
9. Any other information, statements, or warnings required for any of the drug products contained therein.
